



NEWS RELEASE

CareDx and Illumina Enter into Supply Agreement for Next Generation Sequencing Technologies

Agreement expands technology capabilities at CareDx Reference Lab

Brisbane, CA, June 16, 2014, CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it has entered into a multi-year supply agreement with Illumina, Inc. that will provide access to next generation sequencing, microarray equipment and consumables to the CareDx reference and R&D laboratories.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function.

“We’re pleased to enter into this non-exclusive relationship with Illumina, the world’s leader in next generation sequencing technology,” said Peter Maag, President and CEO of CareDx. “As we expand our pipeline of high-value, transplant diagnostic surveillance solutions from the gene expression-based AlloMap® to cell-free DNA-based tests, we believe the technology solutions from Illumina will effectively support our development and commercialization efforts.”

“CareDx is a recognized leader in heart transplant diagnostics, and we are pleased to have been selected as a strategic partner to expand their technology capabilities in the field of transplantation using next generation sequencing,” said Rick Klausner, M.D., Chief Medical Officer of Illumina.

About AlloMap®

AlloMap MolecularTesting is a non-invasive gene expression test used to aid in the identification of heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the XDX CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive gene-expression test and surveillance solutions for transplant recipients. The company commercializes AlloMap, which aids clinicians in identifying heart transplant recipients with stable graft function.

For more information, please visit: www.CareDxInc.com.

Contacts

Company

Bradley P. Sherrill
Senior Director, Marketing
Tel: 415-287-2397
bsherrill@CareDxInc.com